| pubmed-article:11948467 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0853879 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0903677 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0812305 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C1527244 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C1704265 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:11948467 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:11948467 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11948467 | pubmed:dateCreated | 2002-4-11 | lld:pubmed |
| pubmed-article:11948467 | pubmed:abstractText | To assess the frequency and prognostic impact of Ep-CAM and Her-2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow-up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep-CAM and Her-2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her-2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep-CAM and Her-2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep-CAM and Her-2/neu overexpression were predictive for poor disease-free (DFS) and disease-related overall survival (DROS). Concurrent Ep-CAM and Her-2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her-2/neu and Ep-CAM overexpression. By multivariate analysis Ep-CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her-2/neu overexpression. In conclusion, overexpression of Ep-CAM and Her-2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. | lld:pubmed |
| pubmed-article:11948467 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11948467 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11948467 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11948467 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11948467 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:GunsiliusEber... | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:MikuzGregorG | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:EnsingerChris... | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:TheurlIgorI | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:SpizzoGilbert... | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:ObristPeterP | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:DünserMartina... | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:RamoniAngelaA | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:EiblGüntherG | lld:pubmed |
| pubmed-article:11948467 | pubmed:author | pubmed-author:GastlGüntherG | lld:pubmed |
| pubmed-article:11948467 | pubmed:copyrightInfo | Copyright 2002 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:11948467 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11948467 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:11948467 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:11948467 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11948467 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11948467 | pubmed:pagination | 883-8 | lld:pubmed |
| pubmed-article:11948467 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:meshHeading | pubmed-meshheading:11948467... | lld:pubmed |
| pubmed-article:11948467 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11948467 | pubmed:articleTitle | Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. | lld:pubmed |
| pubmed-article:11948467 | pubmed:affiliation | Division of Hematology and Oncology, University of Innsbruck, Innsbruck, Austria. | lld:pubmed |
| pubmed-article:11948467 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11948467 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11948467 | lld:pubmed |
